Table 2.
Measures According to Theoretical Constructs and Times of Collection.
| Constructs | Measures | Timea |
|---|---|---|
| Health outcomes | ||
| Medication adherence | BETRCap data | Daily |
| Self-report measure for medication adherence—collected by weekly app assessment (3 items, α = 0.83) | Weekly | |
| Clinical outcomes | Viral load—collected by nurse | BL, 6 mo |
| TFV-DP levels (DBS)—collected by nurse | IPI | |
| ART levels hair sample—self-collected | BL, IPI | |
| Urine Tenofovir POC test—self-collected | BL, IPI, 3 mo, 6 mo | |
| Medical appointment attendance | Clinic attendance records—extracted from medical records | BL, 6 mo |
| Couple interactions | ||
| Social support | Medication specific social support (8 items, α = 0.92); Social support and relationship satisfaction—weekly app assessment | BL, IPI, 3 mo, 6 mo |
| Relationship satisfaction | Global distress scale—marital satisfaction inventory revised (22 items, α = 0.95) | BL, IPI, 3 mo, 6 mo |
| Self-regulation | ||
| Knowledge of ART | HIV treatment knowledge inventory (12 items, α = 0.70) | BL, IPI, 3 mo, 6 mo |
| Knowledge of treatment | Knowledge of personal treatment regimen | BL, IPI, 3 mo, 6 mo |
| Adherence attitudes | Attitudes about HIV Medications (11 items, α = 0.70) | BL, IPI, 3 mo, 6 mo |
| Substance use | Alcohol use disorders identification test (AUDIT) (10 items, α = 0.85); drug abuse screening test (DAST) (10 items, α = 0.94); drug treatment history | BL, IPI, 3 mo, 6 mo |
| Self-efficacy | Adherence self-efficacy (13 items, α = 0.96) | BL, IPI, 3 mo, 6 mo |
| Risk behaviors | Sexual risk and substance use risk behaviors | BL, IPI, 3 mo, 6 mo |
| Contextual influences | ||
| Background | Demographics | BL |
| Environmental stress | Economic and food insecurity, stressful life events | BL, IPI, 3 mo, 6 mo |
| Stigma | Social impact scale for HIV (24 items, α = 0.85); drug use stigma (9 items, α = 0.80) | BL, IPI, 3 mo, 6 mo |
BL = baseline, IPI = immediately post-intervention (1 month), 3 mo = 3-month follow-up, 6 mo = 6-month follow-up.